{
  "figure_1": "Study flow diagram.",
  "figure_2": "Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.",
  "figure_3": "Risk of bias summary: review authors' judgements about each risk of bias item for each included study.",
  "figure_4": "Comparison 1: Radiation therapy versus control, Outcome 1: Loss of 3 or more lines best‐corrected visual acuity lost at 12 months",
  "figure_5": "Comparison 1: Radiation therapy versus control, Outcome 2: Three or more lines visual acuity lost at 24 months",
  "figure_6": "Comparison 1: Radiation therapy versus control, Outcome 3: Change in BCVA at 12 months",
  "figure_7": "",
  "figure_8": "Comparison 1: Radiation therapy versus control, Outcome 5: Change in contrast sensitivity",
  "figure_9": "Comparison 2: Radiation therapy with anti‐VEGF versus anti‐VEGF alone, Outcome 1: Three or more lines visual acuity lost at 12 months",
  "figure_10": "Comparison 2: Radiation therapy with anti‐VEGF versus anti‐VEGF alone, Outcome 2: Three or more lines visual acuity lost at 24 months",
  "figure_11": "Comparison 2: Radiation therapy with anti‐VEGF versus anti‐VEGF alone, Outcome 4: Change in BCVA at 24 months",
  "figure_12": "Comparison 1: Radiation therapy versus control, Outcome 4: Change in BCVA at 24 months",
  "figure_13": "Comparison 1: Radiation therapy versus control, Outcome 6: Contrast sensitivity raw data",
  "figure_14": "Comparison 2: Radiation therapy with anti‐VEGF versus anti‐VEGF alone, Outcome 3: Change in BCVA at 12 months"
}